February 5, 2019. FDA needs to maintain high standards for evidence of effectiveness and safety whether the source of the data is from traditional clinical trials or RWE. Double-blind, randomized clinical trials remain the gold standard, and along with other types of well-controlled trials (including those that generate RWE), provide information that observational studies cannot. RWE should supplement rather than replace traditional, randomized and blinded controlled clinical trials except in situations where such traditional clinical trials are not possible.
Read More »On Health Policy
USPSTF Draft Recommendations on Hepatitis B Virus Screening in Pregnant Women
February 4, 2019. We support USPSTF’s draft recommendation on hepatitis B virus infection screening in all pregnant women.
Read More »NCHR Comments on USPSTF’s Draft Research Plan for Colorectal Cancer: Screening
January 30, 2019. We strongly support the USPSTF’s efforts to update recommendations for different types of colorectal cancer screening for different demographic subgroups, as well as their broader efforts to improve the health of all Americans by making evidence-based recommendations about clinical preventive services.
Read More »Prepared Statement to the Greenwich Board of Estimate and Taxation Regarding Dangers of Artificial Turf, January 24, 2019
January 24, 2019. NCHR President Dr. Diana Zuckerman presented comments in Greenwich, CT regarding the possibility of artificial turf being used in their schools and fields.
Read More »NCHR Letter to Senators Regarding the Impact of the Government Shutdown on Patient Safety
January 11, 2019. NCHR authored a letter to senators regarding the effects of the government shutdown on the FDA and, therefore, patient safety.
Read More »